Table 4.
Rates of axillary upstaging and downstaging in women with node-positive breast cancer undergoing neoadjuvant endocrine therapy
| Clinical nodal stage | Total | |||
|---|---|---|---|---|
| N1 | N2 | N3 | ||
| Overall | ||||
| Total | 3477 | 703 | 400 | 4580 |
| N0 | 535 | 80 | 48 | 663 |
| N1 | 1656 | 146 | 75 | 1877 |
| N2 | 852 | 356 | 90 | 1298 |
| N3 | 434 | 121 | 187 | 742 |
| Downstage | 535 (15.39) | 226 (32.15) | 213 (53.25) | 974 (21.27) |
| No change | 1656 (47.63) | 356 (50.64) | 187 (46.75) | 2199 (48.01) |
| Upstage | 1286 (36.99) | 121 (17.21) | 0 | 1407 (30.72) |
| Ductal | ||||
| Total | 2356 | 483 | 274 | 3113 |
| N0 | 378 | 58 | 39 | 475 |
| N1 | 1193 | 110 | 56 | 1359 |
| N2 | 572 | 247 | 69 | 888 |
| N3 | 213 | 68 | 110 | 391 |
| Downstage | 378 (16.04) | 168 (34.78) | 164 (59.85) | 710 (22.81) |
| No change | 1193 (50.64) | 247 (51.14) | 110 (40.15) | 1550 (49.79) |
| Upstage | 785 (33.32) | 68 (14.08) | 0 | 853 (27.40) |
| Lobular | ||||
| Total | 639 | 141 | 67 | 847 |
| N0 | 84 | 17 | 4 | 105 |
| N1 | 245 | 17 | 3 | 265 |
| N2 | 158 | 72 | 9 | 239 |
| N3 | 152 | 35 | 51 | 238 |
| Downstage | 84 (13.15) | 34 (24.11) | 16 (23.88) | 134 (15.82) |
| No change | 245 (38.34) | 72 (51.06) | 51 (76.12) | 368 (43.45) |
| Upstage | 310 (48.51) | 35 (24.82) | 0 | 345 (40.73) |